FDA Approves First OTC Acetaminophen/Naproxen Combo for 12-Hour Pain Relief
KVUE sits 37% above its 52-week low of $14.02 on light trading volume (0.2× avg).
Summary
The FDA approved Tylenol with Naproxen, the first over-the-counter combination of acetaminophen and naproxen for 12-hour pain relief. This is a significant regulatory win for Kenvue, expanding its flagship Tylenol franchise into a new dual-action category. The approval comes just weeks after a federal appeals court revived hundreds of lawsuits alleging Tylenol use during pregnancy causes autism, adding a positive catalyst that could offset litigation overhang. The new product could strengthen Kenvue's consumer health portfolio and drive revenue growth in the competitive OTC pain relief market. Watch for launch timing and initial sales data in upcoming quarters.
At the time of this announcement, KVUE was trading at $19.19 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.8B. The 52-week trading range was $14.02 to $22.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.